RxDoctor Payments Data

Uchechukwu Ifeji

Psychiatric/Mental Health · Silver Spring, MDNPI 1043736846

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 27.9% of the total. Reporting peaked in 2023 at $1,615 and has fallen 57.7% since, to $683 in 2025. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,956in general payments, 2019–2025

Across 191 payments — averaging $25.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Teva Pharmaceuticals USA, Inc.$706
  • Indivior Inc.$566
  • USWM, LLC$421
  • Alkermes, Inc.$398
  • Gilead$286
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$4,953100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,956 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$32,469
Medicare patients
79
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl100$15,771
Lurasidone Hcl19$4,144
Aripiprazole13$1,374
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine15$970
Atomoxetine Hcl16$804
Buprenorphine Hcl27$607
Bupropion XlBupropion Hcl25$553
Olanzapine20$540
Hydroxyzine Hcl43$530
Quetiapine Fumarate39$509
Trazodone Hcl34$404
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine16$323
Gabapentin28$312
Buspirone Hcl33$168
Venlafaxine Hcl ErVenlafaxine Hcl26$147

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →